GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » 3-Year FCF Growth Rate

Propanc Biopharma (Propanc Biopharma) 3-Year FCF Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma 3-Year FCF Growth Rate?

Propanc Biopharma's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Competitive Comparison of Propanc Biopharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Propanc Biopharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Propanc Biopharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's 3-Year FCF Growth Rate falls into.



Propanc Biopharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Propanc Biopharma  (OTCPK:PPCB) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Propanc Biopharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Propanc Biopharma (Propanc Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Executives
Josef Zelinger director 59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano officer: CFO & Secretary C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon director BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz director, officer: CEO, CFO, Secretary, Treasurer 1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146